AstraZeneca Investor Day Presentation Deck
Key secondary endpoint: overall survival
14
Overall survival probability, %
100
80
8
40
20
0
Patients Still at Risk:
0
Censor
+T-DXd (n = 261)
T-DM1 (n = 263)
4
2 3
+
1
5 6
7
T-DXd (261) 261 256 250 244 240 224 214 202
T-DM1 (263) 263 252 200 163 155 132 108 96
8
9 10 11 12 13
200 183
93
78
14
15 16 17
Time, months
18
19
▬▬▬▬▬▬▬▬▬
+|||||||| H|#####+
20
HHHHHH
MOS, mo (95% CI)
12-mo OS rate, % (95%
CI)
HR (95% CI)
21 22 23
24
25
45
36
29
10
6
168 164 150 132 112 105 79 64 53
25 19
65 60 51 43 37 34 29 23 21 16 12 8 6 4 1 1
26
LO
+
+++
T-DXd
NE (NE-NE)
94.1
90.3-96.4
27
++
T-DM1
NE (NE-NE)
85.9
80.9-89.7
0.56 (0.36-0.86)
P = .007172a
28 29 30 31
32 33
5 3 2 000 00
1 1 1 1 1 1 0 0
B
Early OS data with relatively few events (33 in the T-DXd arm, 53 in the T-DM1 arm)
a) P = .007172, but does not cross pre-specified boundary of P < .000265View entire presentation